Press Release

MONTREAL, November 6, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced its presentation of the latest follow-up data from its ongoing REP 401 study at the 2018 meeting of the American Association for the Study of Liver Disease (AASLD) to be held November 9 – 13, 2018 in San Francisco,CA, USA.

The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of REP 2139-Mg and REP 2165-Mg when used in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in patients with chronic HBeAg negative HBV infection.

Replicor’s poster presentation (Poster 393), to be presented on Friday, November 9, 2018, will showcase the on-going follow-up analysis after removal of all treatment (now beyond 24 weeks in most patients) indicating normalization of liver function and the stable maintenance of either inactive HBV or functional cure of HBV, both endpoints where therapy is not further indicated under current guidelines.

This presentation will expand on the existing clinical data demonstrating the unique ability of nucleic acid polymer (NAP)-based combination therapy to eliminate serum HBsAg in most patients and the unique ability of NAPs to achieve functional cure in patients with HBV and HBV / HDV co-infection when combined with immunotherapy.

The clinical development of REP 2139-Mg and its unique ability to achieve functional cure in HBV and HDV will also be featured at the 2018 HBV Cure Workshop , to be held on November 7, 2018 in Toronto, Canada and at the 16th Hepatitis Delta International Network Meeting, to be held on November 10, 2018 as part of the AASLD 2018 meeting.

Replicor’s presentations from all of these meetings will be available on the company’s website following their disclosure at For further information about the 2018 AASLD Meeting visit: For the 2018 HBV Cure Workshop visit:

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at

Media Contact:
Natacha Dorget
(514) 733-1998